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Abstract 
Background: Acetaminophen (APAP)-induced acute liver failure (ALF) is associated with significant mortality due to 
intracranial hypertension (ICH), a result of cerebral edema (CE) and astrocyte swelling. Brain-type fatty acid-binding 
protein (FABP7) is a small (15 kDa) cytoplasmic protein abundantly expressed in astrocytes. The aim of this study was 
to determine whether serum FABP7 levels early (day 1) or late (days 3–5) level were associated with 21-day mortality 
and/or the presence of ICH/CE in APAP-ALF patients.
Methods: Serum samples from 198 APAP-ALF patients (nested case–control study with 99 survivors and 99 non-sur-
vivors) were analyzed by ELISA methods and assessed with clinical data from the US Acute Liver Failure Study Group 
(ALFSG) Registry (1998–2014).
Results: APAP-ALF survivors had significantly lower serum FABP7 levels on admission (147.9 vs. 316.5 ng/ml, 
p = 0.0002) and late (87.3 vs. 286.2 ng/ml, p < 0.0001) compared with non-survivors. However, a significant association 
between 21-day mortality and increased serum FABP7 early [log FABP7 odds ratio (OR) 1.16, p = 0.32] and late (log 
FABP7 ~ OR 1.34, p = 0.21) was not detected after adjusting for significant covariates (MELD, vasopressor use). Areas 
under the receiver-operating curve for early and late multivariable models were 0.760 and 0.892, respectively. In a 
second analysis, patients were grouped based on the presence (n = 46) or absence (n = 104) of ICH/CE. A significant 
difference in FABP7 levels between patients with or without ICH/CE at early (259.7 vs. 228.2 ng/ml, p = 0.61) and late 
(223.8 vs. 192.0 ng/ml, p = 0.19) time points was not identified.
Conclusion: Serum FABP7 levels were significantly elevated at early and late time points in APAP-ALF non-survivors 
compared to survivors. However, significant differences in FABP7 levels by 21-day mortality were not ascertained after 
adjusting for significant covariates (reflecting severity of illness). Our study suggests that FABP7 may not discriminate 
between patients with or without intracranial complications.
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Background
Acute liver failure (ALF) is defined by the occurrence 
of hepatic encephalopathy (HE) and hepatic synthetic 
dysfunction within 26  weeks of the first symptoms of 
liver disease [1]. Severe coagulopathy, encephalopathy 
and hemodynamic instability contribute to a picture of 
multiorgan failure. Currently, the most common cause 
of ALF in North America is acetaminophen (APAP) [2]. 
Particularly in APAP-induced ALF, cerebral edema (CE) 
and intracranial hypertension (ICH) are major causes of 
morbidity and mortality [3]. The pathogenesis for ICH 
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and CE in ALF is not fully understood, but astrocyte 
swelling causing cellular dysfunction as well as increased 
cerebral blood flow is believed to be implicated [4]. The 
degree of hyperammonemia has been demonstrated to 
be associated with ICH [5]. Ammonia, as a gas  (NH3) and 
ion  (NH4+), freely crosses the blood–brain barrier and is 
primarily removed by glutamine synthetase, an enzyme 
solely found in astrocytes within the brain [6]. Glutamine 
synthetase catalyzes the amidation of glutamate to glu-
tamine that subsequently leads to hyperosmotic changes 
and astrocyte swelling. However, studies have shown that 
hyperammonemia alone does not predict ICH [7].
Given the challenges presented in managing critically 
ill ALF patients with potential CE/ICH including the 
consideration for liver transplant (LT), the development 
of a noninvasive biomarker with the potential to predict 
ICH would be of great value, especially given the signifi-
cant bleeding risks of invasive intracranial pressure mon-
itoring in these coagulopathic patients [8].
Fatty acid-binding proteins (FABP) are small (15  kDa) 
cytoplasmic proteins that are abundantly expressed in tis-
sues with active fatty acid metabolism, such as brain and 
liver. The primary function of FABPs is the intracellular 
transport of long-chain fatty acids [9]. The cellular expres-
sion of FABPs is responsive to changes in lipid metabolism, 
which can be induced during pathophysiological condi-
tions, such as ischemia/inflammation or pharmacological 
stimuli [10]. Brain-type FABP (FABP7) is solely expressed 
in brain, exclusively in astrocytes [11]. Previous investiga-
tions have shown serum levels of FABP7 to be elevated in 
patients with various neurological diseases including stroke 
[12] and dementia [13]. While our group recently demon-
strated the prognostic value of serum levels of liver-type 
FABP (FABP1) in ALF, to date FABP7 as a biomarker for 
the risk of ICH in ALF has not been investigated [14].
This nested case–control study of randomly selected sam-
ples from prospectively enrolled patients from the US Acute 
Liver Failure Study Group (ALFSG) registry aimed to exam-
ine levels of FABP7 in APAP-ALF patients. Specifically, our 
primary objectives were to test the following hypotheses
(a) Higher FABP7 serum levels are significantly associ-
ated with 21-day transplant-free mortality (in the 
absence of transplant) after adjusting for other signifi-
cant covariates (Analysis 1).
(b) Elevated serum levels of FABP7 in APAP-ALF are sig-
nificantly associated with ICH/CE after adjusting for 
other significant covariates (Analysis 2).
Methods
This study is a nested case–control study of prospectively 
collected data and biosamples of 198 patients enrolled 
in the US ALFSG registry/biorepository and is outlined 
in detail in Additional file  1: Figure S1. Between Janu-
ary 1998 and December 2014, 1027 APAP-ALF patients 
were enrolled in the registry from which 704 patients 
were alive at day 21 in the absence of LT. We identified 
124 survivors with early and late serum samples from 
which 99 were randomly selected for analysis. Of 224 
patients who died in the absence of LT, 87 patients with 
early and late samples were also included in this analy-
sis. A further 12 patients with exclusively an early sample 
(of a possible 92) were randomly selected for inclusion 
in this analysis. Personnel not involved in the analysis 
of the samples or statistical analysis for the paper per-
formed random selection of patients. All enrolling cent-
ers were tertiary academic centers, and all but one were 
LT centers. The authors’ Institutional Review Board 
(IRB)/Health research ethics boards of all enrolling US 
ALFSG sites have approved all research, and all clinical 
investigation has been conducted according to the princi-
ples expressed in the 1975 Declaration of Helsinki. Given 
patients were unable to provide written consent (critical 
illness, HE), written assent was obtained from the next of 
kin from each patient. Each center implemented moni-
toring and therapeutic interventions according to insti-
tutional standards of care. Reporting of the analysis of 
this study followed the STROBE Guidelines for reporting 
case–control studies [15]. Consistent with ALFSG stud-
ies [16], the primary outcome (Analysis 1) was 21-day 
LT-free survival (no patients included in the analysis 
received LT). Secondary outcome (Analysis 2) was the 
development of ICH/CE.
Participants
Inclusion criteria were: (1) evidence of ALF according to 
the enrollment criteria for the ALFSG (see operational 
definitions); (2) age ≥  18  years; (3) HE during the first 
seven days of study admission (West Haven Criteria) 
[17]; and (4) patients within the ALFSG registry with 
primary diagnoses of APAP determined by the site inves-
tigator. Exclusion criteria were: (1) cirrhosis/acute-on 
chronic liver failure; (2) patients without a primary diag-
nosis of APAP; and (3) patients who received a LT. Serum 
samples were analyzed on study admission (early; day 1) 
and late (either day 3, 4 or 5) where available. Patients 
who received a LT were excluded from our study because 
listing for transplant is a clinical decision, which is not 
standardized among ALFSG sites. A further 51 healthy 
controls were analyzed (University of Alberta) for FABP7 
only.
Operational definitions
For the purposes of this study, ALF was defined as 
INR ≥ 1.5 and HE within the first 26 weeks of liver dis-
ease in a patient with an acute hepatic insult [18]. HE 
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coma grade was defined by the West Haven Criteria (sim-
plified) as follows: grade 1 ~ any alteration in mentation, 
grade 2 being somnolent or obtunded but easily rousable 
or presence of asterixis, grade 3 being rousable with dif-
ficulty, and grade 4 being unresponsive to deep pain [17]. 
In this study, we defined ‘low coma grade’ as grade 1 or 
2 and ‘high coma grade’ as grade 3 or 4. The KCC [19] 
predicts poor outcome (death/transplant) if: (a) pH is 
less than 7.3 or (b) if INR is greater than 6.5, creatinine 
is greater than 3.4 mg/dl, and coma grade is high (3 or 4). 
The model for end-stage liver disease (MELD) is defined 
as 10*(0.957*log(4) +  0.378*log(bilirubin) +  1.12*log(IN
R)) for dialyzed patients and 10*(0.957*log(creatinine) 
+  0.378*log(bilirubin) +  1.12*log(INR)) for patients not 
dialyzed [20].
Laboratory Assays of FABP7
FABP7 was measured in serum samples with a solid-
phase enzyme-linked immunosorbent assay (ELISA) 
following manufacturer’s instructions (Biomatik, USA). 
Briefly, samples were incubated 2  h on a monoclonal 
anti-FABP7 pre-coated plate. A specific FABP7 biotin-
conjugated polyclonal antibody solution was added for 
2 h. After washing plates, avidin conjugated to horserad-
ish peroxidase was added for 30  min. Finally, substrate 
tetramethylbenzidine was added for 15  min. Reactions 
were stopped by addition of sulfuric acid, and absorbance 
was read at 450  nm. Standard curve ranges from 0.47 
to 30  ng/ml. Samples were performed in duplicate and 
accepted valid with a variation coefficient less than 25%.
Statistical methods aim one: FABP7 and 21‑day survival 
in APAP‑ALF
For differences between outcome groups (APAP-ALF 
survivors, n  =  99, APAP-ALF non-survivors, n  =  99), 
categorical variables were compared using the Chi-
squared test or Fisher’s exact test (if n  <  10 in any cell 
of the two-by-two table). FABP7 was treated as a con-
tinuous variable. Continuous variables were reported as 
medians with interquartile range (IQR) and compared 
using the Wilcoxon rank-sum test. Survival was defined 
as the dichotomous outcome, alive or dead at 21  days 
after enrollment into the registry (no patients received 
a LT in this analysis). A two-sided p value of < 0.05 was 
considered statistically significant for all comparisons 
(Additional file 2).
In order to control for variables that may confound 
the effect of FABP7 on 21-day mortality, logistic regres-
sion analysis was performed [21]. Aside from FABP7, 
covariates considered in multivariable modeling included 
MELD, lactate, vasopressors use, RRT, MV and high 
coma grade. Separate multivariable (logistic) regression 
models were derived for FABP7 early (day 1) and late 
(days 3–5) by including variables, which were significant 
on univariate analysis and performing backward elimina-
tion with a p value threshold of 0.05.
Statistical methods aim two: FABP7 and ICH in APAP‑ALF
In this secondary analysis, the outcome of interest exam-
ined was intracranial hypertension (ICH) either based on 
(a) intracranial pressure monitoring with ICP  >  25  mm 
Hg or based on (b) computed tomography (CT) imaging 
of the brain. CT evidence of cerebral edema was defined 
as a hypodense signal, effacement of the gray white 
matter junction, loss of differentiation of the lenticular 
nucleus and decreased visualization of the sulci, insula 
and cisterns [22]. Out of the 150 APAP-ALF patients 
where data were available to determine the presence or 
absence of ICH, 46 deceased patients had evidence of 
ICH based on these criteria. Statistical methods for this 
analysis will be similar to the first analysis except the 
primary outcome (ICH). Multivariable logistic regres-
sion analysis (as described above) was performed [21] 
to assess independent variables associated with ICH 
including FABP7. The pre-specified prognostic vari-
ables were based on previous publications [5] included 
at admission into the registry; age, lactate value, MELD 
[20] score (admission) and other variables with statistical 
significance on univariable analysis. Model performance 
for both Aim 1 and Aim 2 was assessed using area under 
the receiver-operating curve (AUROC) and the Hosmer–
Lemeshow test for goodness of fit. SAS software version 
9.3 was used for univariate comparisons and multivari-
able logistic regression modeling.
Results
Analysis one: comparative analysis of 198 APAP‑ALF 
patients
Demographic and clinical outcomes stratified by mortal-
ity (alive at day 21, n = 99; deceased, n = 99) are listed 
in Table 1. No patients in this analysis received LT. Com-
paring APAP-ALF survivors and non-survivors at day 21, 
survivors required significantly less organ support during 
the 7 days of inpatient study (MV 65 vs. 93%; vasopres-
sors 12 vs. 70%; RRT 27 vs. 45%; p < 0.008 for all). Sur-
vivors were less likely to achieve high (3 or 4) HE coma 
grade (62 vs. 93%, p  <  0.0001) and less likely to receive 
mannitol for intracranial hypertension (22 vs. 46%, 
p = 0.0003). APAP-ALF survivors were less likely to have 
complications during the first 7  days of study includ-
ing seizures (3 vs. 21%, p < 0.0001), arrhythmias (25 vs. 
38%, p =  0.047) or gastrointestinal bleeding (8 vs. 19%, 
p  =  0.037). On admission, 7% of APAP-ALF survivors 
and 16% of non-survivors met KCC (p =  0.13). Among 
the 99 APAP-ALF non-survivors, the most common 
causes of death reported were multiorgan failure (53%) 
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and neurological complications (38%). Cause of death 
was unknown in 9% of cases.
Clinical parameters in 198 APAP‑ALF patients: admission 
(early)
Comparisons of clinical parameters on study admission 
are listed in Table 2. APAP-ALF survivors demonstrated 
significantly lower MELD scores (23 vs. 29, p  <  0.0001) 
than non-survivors on admission. Survivors were 
significantly less likely to be on organ support (MV 58 
vs. 80%, p = 0.0007; vasopressors, 9 vs. 42%, p < 0.0001) 
or achieve high HE grade (57 vs. 71%, p  =  0.034) on 
admission.
FABP7 levels at admission (early) are listed in 
Table  2 and graphically shown in Fig.  1. APAP-ALF 
survivors had significantly lower admission serum 
FABP7 levels (147.9 vs. 316.5  ng/ml) compared with 
non-survivors (p = 0.0002). In comparison, 52 healthy 
Table 1 Demographic, clinical and biochemical parameters in 198 APAP-ALF patients by outcome
N frequency, IQR interquartile range, ARDS acute respiratory syndrome, CT computed tomography, CXR chest x-ray
APAP alive day 21 (n = 99) APAP dead day 21 (n = 99) p value
N Number (%) or median (IQR) N Number (%) or median (IQR)
Age 99 35 (28–43) 99 40 (30–48) 0.084
Sex (female) 99 75 (76%) 99 72 (73%) 0.63
Race 0.23
 White 99 83 (84%) 99 79 (80%)
 African-American 99 8 (8%) 99 15 (15%)
 Other 99 8 (8%) 99 5 (5%)
Organ support (days 1–7)
 Mechanical ventilation 99 64 (65%) 99 93 (93%) < 0.0001
 Vasopressors 99 12 (12%) 99 69 (70%) < 0.0001
 Renal replacement therapy 99 27 (27%) 99 45 (45%) 0.0078
KCC 87 7 (7%) 87 16 (16%) 0.13
Coma grade 3/4 (worst days 1–7) 99 61 (62%) 98 91 (93%) < 0.0001
ICP-directed therapies (days 1–7)
 ICP monitor 99 12 (12%) 99 21 (21%) 0.086
 Mannitol 99 22 (22%) 99 46 (46%) 0.0003
 Hypertonic saline 99 11 (11%) 99 14 (14%) 0.52
 Barbiturates 99 9 (9%) 99 20 (20%) 0.043
 Hypothermia 99 17 (17%) 99 14 (14%) 0.56
 Sedatives 99 70 (71%) 99 88 (89%) 0.0014
Blood products (days 1–7)
 Red blood cells 99 34 (34%) 99 50 (51%) 0.021
 Fresh-frozen plasma 99 50 (51%) 99 76 (77%) 0.0001
 Recombinant VIIA 99 3 (3%) 99 5 (5%) 0.72
 Platelets 99 17 (17%) 99 36 (36%) 0.0023
ICU complications (days 1–7)
 Seizures 99 3 (3%) 99 21 (21%) < 0.0001
 Arrhythmias 99 25 (25%) 99 38 (38%) 0.047
 GI bleeding 99 8 (8%) 99 19 (19%) 0.037
 ARDS 99 0 (0%) 99 3 (3%) 0.25
 CT (cerebral edema) 55 7 (13%) 72 32 (44%) < 0.001
 Abnormal CXR 99 88 (89%) 99 83 (84%) 0.30
 Bacteremia/blood stream infection 99 7 (7%) 99 10 (10%) 0.61
Cause of death
 Multiorgan failure 99 52 (53%)
 Cerebral edema 99 38 (38%)
 Unknown 99 9 (9%)
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Table 2 Demographic, clinical and biochemical parameters in 198 APAP-ALF patients by outcome (admission)
Early (admission) APAP alive day 21 (n = 99) APAP dead day 21 (n = 99) p value
N Number (%) or median (IQR) N Number (%) or median (IQR)
Biochemistry
 Hemoglobin (g/dl) 99 10.4 (9.2–12.5) 97 10.9 (9.5–12.2) 0.52
 White blood count  (109/l) 98 8.6 (6.4–11.2) 97 10.9 (7.3–17.5) 0.0008
 Platelet count  (109/l) 98 132.5 (90.0–195.0) 97 110.0 (67.0–160.0) 0.0045
 INR 99 2.7 (1.8–4.1) 96 3.4 (2.3–4.8) 0.0023
 ALT (IU/l) 98 3380 (1949–6576) 99 3235 (1483–5716) 0.37
 Bilirubin (mg/dl) 98 4.1 (2.5–5.6) 99 5.0 (3.6–7.8) < 0.0001
 pH 88 7.4 (7.4–7.5) 88 7.4 (7.3–7.5) 0.22
 Ammonia (venous) (μmol/l) 51 92 (73–140) 32 139 (72–205) 0.068
 Creatinine (mg/dl) 98 1.4 (0.8–3.0) 98 2.6 (1.2–3.8) 0.0007
 Lactate (mmol/l) 71 2.8 (1.7–5.5) 68 7.0 (4.8–11.8) < 0.0001
 Phosphate (mg/dl) 88 2.3 (1.7–3.4) 76 3.2 (2.1–4.5) 0.0061
MELD 98 23.4 (12.7–27.7) 96 29.1 (23.8–34.5) < 0.0001
High coma grade (3 or 4) 99 56 (57%) 97 69 (71%) 0.034
Organ support
 Mechanical ventilation 99 57(58%) 99 79 (80%) 0.0007
 Vasopressors 99 9 (9%) 99 42 (42%) < 0.0001
 Renal replacement therapy 99 19 (19%) 99 24 (24%) 0.39
FABP7 (ng/ml) 99 147.9 (66.6–296.2) 99 316.5 (119.8–562.2) 0.0002
Late (n = 186) APAP alive day 21 (n = 99) APAP dead day 21 (n = 87) p value
Late (days 3–5) N Number (%) or median (IQR) N Number (%) or median (IQR)
Biochemistry
 Hemoglobin (g/dl) 94 9.9 (9.0–11.1) 81 10.2 (9.2–10.9) 0.63
 White blood count  (109/L) 94 8.1 (5.9–11.6) 81 11.3 (7.1–15.0) 0.0029
 Platelet count  (109/L) 95 111.0 (68.0–153.0) 81 66.0 (47.0–100.0) < 0.0001
 INR 94 1.5 (1.3–1.8) 75 2.5 (1.8–4.4) < 0.0001
 ALT (IU/L) 94 1172 (612–2007) 78 938 (383–1995) 0.31
 Bilirubin (mg/dl) 92 5.5 (2.7–8.2) 78 9.8 (6.7–13.7) < 0.0001
 pH 55 7.4 (7.4–7.5) 76 7.4 (7.3–7.5) 0.042
 Ammonia (venous) (μmol/L) 25 62 (44–84) 17 119 (78–133) 0.0038
 Creatinine (mg/dl) 94 1.2 (0.7–2.5) 82 2.4 (1.3–4.0) < 0.0001
 Lactate (mmol/L) 31 1.7 (1.0–2.2) 41 3.8 (2.6–6.7) < 0.0001
 Phosphate (mg/dl) 73 2.8 (2.3–3.6) 35 3.3 (2.5–4.5) 0.054
PO2/FiO2 ratio 48 3.3 (2.1–4.5) 71 2.5 (1.4–3.9) 0.0087
MELD 87 14.2 (5.4–24.6) 73 29.7 (23.5–35.4) < 0.0001
High coma grade (3 or 4)a 59 35 (59%) 82 72 (88%) < 0.0001
Organ support
 Mechanical ventilation 99 49 (49%) 88 74 (85%) < 0.0001
 Vasopressors 99 5 (5%) 88 45 (52%) < 0.0001
 Renal replacement therapy 99 10 (19%) 88 27 (31%) 0.062
FABP7 (ng/ml) 99 87.3 (48.0–261.5) 87 286.2 (146.7–536.9) < 0.0001
N frequency, IQR interquartile range, INR international normalized ratio, AST aspartate aminotransferase, ALT alanine aminotransferase, MELD model for end-stage liver 
disease
a Hepatic encephalopathy grade according to West Haven criteria
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controls had median serum levels of 13.5 (8.7–20.2) 
ng/ml.
Clinical parameters in 186 APAP‑ALF patients: days 3–5 
(late)
Comparisons of clinical parameters on days 3–5 (late) 
are listed in Table 2. Of the 99 APAP-ALF non-survivors, 
samples of late time points were available in 87 patients 
as 12 died before days 3–5. APAP-ALF survivors (n = 99) 
were significantly less likely to be on MV (49 vs. 85%, 
p  <  0.0001) and vasopressors, (5 vs. 52%, p  <  0.0001) 
or achieve high HE grade (59 vs. 88%, p  <  0.0001) than 
non-survivors.
Late (days 3–5) FABP7 are listed in Table 2 and graphi-
cally shown in Fig.  1. APAP-ALF survivors had signifi-
cantly lower late serum FABP7 levels (87.3 vs. 286.2 ng/
ml) compared with non-survivors (p  <  0.0001). FABP7 
levels were significantly higher in all ALF patients (survi-
vors and non-survivors) compared to healthy controls for 
both early and late time points (p < 0.0001).
Multivariable analysis: associations with 21‑day mortality
In order to adjust for covariates, multivariable logistic 
regression for 198 APAP-ALF patients to determine asso-
ciations (adjusted) with 21-day mortality was performed 
(Table  3). Two models were derived: one on admis-
sion (early) and one at days 3–5 (late). Values of serum 
FABP7 were transformed to their natural logarithm (log 
FABP1) to comply with the linearity assumption in logis-
tic regression.
Early (admission) model
FABP7 was not associated with 21-day mortality [odds 
ratio OR 1.001 per increment, 95% CI (1.000, 1.001), 
p  =  0.18] after adjusting for significant covariates 
Fig. 1 Serum levels of FABP7 (ng/ml) in healthy controls, non-survi-
vors (early ~ admission), survivors (early), non-survivors (late ~ days 
3–5), survivors (late)
Table 3 Early (day 1) and late (days 3–5) predictors of 21-day mortality in 198 APAP-ALF patients
Early: lactate (p = 0.52), high coma grade (p = 0.46), and mechanical ventilator (p = 0.084) were not significant on multivariable analysis so not included in the final 
early model
Late: mechanical ventilation (p = 0.69) and high coma grade (p = 0.53) were not significant on multivariable analysis so not included in the final late model. Lactate 
was not included due to missing data
Early Unadjusted Multivariable model (N = 194), AUROC = 0.766
N OR 95% OR CI p value Included in Model OR 95% CI p value
FABP7 198 1.001 (1.000, 1.002) 0.0078 Yes 1.001 (1.000, 1.001) 0.18
MELD 194 1.083 (1.047, 1.119) < 0.0001 Yes 1.056 (1.020, 1.093) 0.0021
Lactate 132 1.205 (1.095, 1.327) 0.0001 No
Vasopressors 198 7.368 (3.335, 16.287) < 0.0001 Yes 4.138 (1.769, 9.677) 0.0011
Renal replacement therapy 198 1.347 (0.683, 2.658) 0.390 No
Mechanical ventilation 198 2.910 (1.547, 5.475) 0.0009 No
High coma grade (3 or 4) 196 1.892 (1.047, 3.421) 0.0348 No
Late (days 3–5) Unadjusted Multivariable model (N = 160), AUROC = 0.891
N OR 95% OR CI p value Included in model OR 95% CI p value
FABP7 186 1.003 (1.001, 1.004) 0.0001 Yes 1.001 (0.999, 1.003) 0.40
MELD 160 1.115 (1.075, 1.157) < 0.0001 Yes 1.084 (1.038, 1.132) 0.0003
Lactate 71 6.908 (2.592, 18.406) 0.0001 No
Vasopressors 186 20.143 (7.462, 54.370) < 0.0001 Yes 20.419 (6.221, 67.021) <0.0001
Renal replacement therapy 186 1.895 (0.964, 3.724) 0.0638 No
Mechanical ventilation 186 5.808 (2.859, 11.802) < 0.0001 No
High coma grade (3 or 4) 141 4.936 (2.129, 11.446) 0.0002 No
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including MELD [OR 1.056 (1.020, 1.093) per increment, 
p =  0.0021] and requirement for vasopressors [OR 4.14 
(1.77, 9.07), p = 0.0011]. This early model demonstrated 
AUROC of 0.766.
Late (days 3–5) model
FABP7 was not associated with 21-day mortality [OR 
1.001 (0.999, 1.003) per increment, p = 0.40] after adjust-
ing for significant covariates including MELD [OR 1.084 
(1.038, 1.132) per increment, p  =  0.0003] and require-
ment for vasopressors [OR 20.42 (6.22, 67.02), p < 0.0001]. 
This late model demonstrated AUROC of 0.891.
Analysis two: comparative analysis of 150 APAP‑ALF 
patients
Demographic and clinical outcomes of 150 patients strat-
ified by the presence (n = 46) and absence (n = 104) of 
ICH/CE based on review of subject data (ICP measure-
ments, CT brain, cause of death) are shown in Additional 
file 3: Table S1. (In 48 patients, the presence or absence 
of ICH/CE could not be determined.) There were no sig-
nificant differences in age (36 vs. 39, p = 0.11) or gender 
(female 74 vs. 69%, p = 0.56). During the 7 days of inpa-
tient study, APAP-ALF patients with ICH/CE had higher 
requirements for ventilation (MV 100 vs. 75%, p < 0.0001) 
and were more likely to achieve high (3 or 4) HE coma 
grade (100 vs. 72%, p < 0.0001). APAP-ALF patients with 
evidence of ICH/CE were less likely to be alive at day 21 
(17 vs. 41%, p = 0.0049) but were more likely to be listed 
for LT (33 vs. 13%, p = 0.0062).
Clinical parameters in 150 APAP‑ALF patients: admission 
(early)
Comparisons of clinical parameters on study admis-
sion are shown in Additional file 4: Table S2. APAP-ALF 
patients with ICH/CE had significantly higher serum 
INR (3.6 vs. 2.9) compared to patients without ICH/CE 
(p = 0.024). On study admission, patients who went on to 
develop ICH/CE were significantly more likely to be on 
mechanical ventilation (MV 85 vs. 65%, p =  0.019) and 
achieve high HE grade (76 vs. 59%, p =  0.043). Admis-
sion (early) levels of FABP7 are listed in Additional file 4: 
Table S2 and graphically shown in Fig. 2. There were no 
significant differences in FABP7 levels on admission 
between APAP-ALF patients with or without ICH/CE 
(259.7 vs. 228.2 ng/ml, p = 0.61).
Clinical parameters in 186 APAP‑ALF patients: days 3–5 
(late)
Comparisons of clinical parameters on days 3–5 (late) 
are shown in Additional file  4: Table S2. Patients who 
developed ICH/CE were significantly more likely to be on 
mechanical ventilation (MV 95 vs. 63%, p < 0.0001) and 
achieve higher grades of HE (100 vs. 75%, p =  0.0004). 
Days 3–5 (late) levels of FABP7 are shown in Additional 
file  4: Table S2 and graphically in Fig.  2. There were no 
significant differences in late FABP7 levels between 
APAP-ALF patients with or without ICH/CE (223.8 vs. 
192.0 ng/ml, p = 0.19).
Multivariable analysis: associations with 21‑day mortality
Multivariable logistic regression for 198 APAP-ALF to 
determine associations (adjusted) with the development 
of ICH/CE was performed (Table  4). Two models were 
derived; one on admission (early) and one at days 3–5 
(late). Values of serum FABP7 were transformed to their 
natural logarithm (log FABP1) to comply with the linear-
ity assumption in logistic regression.
Early (admission) model
FABP7 was not associated with the development of ICH/
CE [OR 1.000 per increment, 95% CI (1.000, 1.001), 
p =  0.65] after adjusting for the only significant covari-
ate, mechanical ventilation [OR 2.880 (1.166, 7.111), 
p =  0.022]. This early model demonstrated AUROC of 
0.590.
Late (days 3–5) model
FABP7 was not associated with the development of ICH/
CE [OR 1.000 per increment, 95% CI (0.999, 1.001), 
p  =  0.57] after adjusting for the only significant covari-
ate, high hepatic coma grade [OR 25.76 (1.40, 472.5), 
p = 0.029]. This late model demonstrated AUROC of 0.641.
Discussion
Key results
In this nested case–control study, we report the first 
published analysis of FABP7 in a large series of 198 
Fig. 2 Serum levels of FABP7 (ng/ml) in healthy controls, cerebral 
edema (early ~ admission), no cerebral edema (early), cerebral edema 
(late ~ days 3–5), no cerebral edema (late)
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well-characterized APAP-ALF patients. Compared with 
survivors, serum FABP7 levels were significantly higher 
at serial time points (early and late) in APAP-ALF non-
survivors. However, significant differences in FABP7 
levels by 21-day mortality were not ascertained after 
adjusting for significant covariates reflecting severity 
of illness (MELD, vasopressor dependence). No differ-
ences in the FABP7 levels were detected for APAP-ALF 
patients with and without evidence of ICH/CE.
Comparison with literature
In our study, ICH/CE was the cause of death in 39% of 
patients, similar to what has been previously reported 
[16]. ICH/CE arises due to astrocyte swelling, cerebral 
vasodilatation, dilated cerebral arterioles and altered cer-
ebral blood flow [23, 24]. Furthermore, it has been shown 
that patients with signs of cerebral edema and ICH have 
increased cerebral blood flow compared to patients with-
out brain edema [25, 26]. Given the bleeding risks associ-
ated with direct intracranial pressure monitoring [8], there 
is an unmet need for noninvasive markers of brain edema 
and ICH to help inform medical decisions. In the setting of 
ALF, astrocyte swelling/injury leads to astrocyte dysfunc-
tion and consequently impairs neuronal function leading 
to HE. However, in parallel, swollen astrocytes release 
small proteins, molecules and osmolytes in response to 
astrocyte hypertonicity to reduce swelling. In the past 
20 years, several biochemical biomarkers have been inves-
tigated for the detection of cerebral injury, including pro-
tein S100b [27], neuron-specific enolase (NSE) [27] and 
glial fibrillary protein (GFAP) [9]. Studies by Strauss et al. 
[27], as well as Vaquero et al. [28], which included 35 and 
54 ALF patients, respectively, concluded that S-100b was 
not a useful marker of neurological outcome in ALF. Fur-
thermore, despite a consistent increase of S-100b in serum, 
levels did not correlate with severity of HE, development 
of brain herniation or outcome. In the same patients, 
Strauss et al. found that serum levels of NSE were higher 
in ALF patients with ICH than those who survived with-
out ICH [27]. However, this univariate comparison did not 
adjust for significant confounding factors/covariates, an 
important limitation to the study.
Major components of the brain are lipids with brain 
cells having a high cell membrane/cytoplasm ratio. Cell 
membranes are formed of lipid bilayers consisting of sat-
urated and unsaturated fatty acids, which can also be oxi-
dized for generating ATP. The primary function of FABPs 
is to facilitate the transport of intracellular long-chain 
fatty acids. In the brain, FABP7 and heart FABP (FABP3) 
are expressed with FABP7 primarily found in astrocytes 
[29] and FABP3 in neurons [30]. With astrocyte swelling 
being a neuropathological landmark of ALF along with 
Table 4 Early (admission) and late (days 3–5) predictors of cerebral edema in 150 APAP-ALF patients
Early: high coma grade (p = 0.69) was not significant on multivariable analysis so not included in the final early model
Late: mechanical ventilation (p = 0.65) was not significant on multivariable analysis so not included in the final late model
*Statistically significant on multivariable analysis
Early Unadjusted Multivariable model (N = 148), AUROC = 0.590
N OR 95% OR CI p value Included in model OR 95% CI p value
FABP7 150 1.000 (1.000, 1.001) 0.58 Yes 1.000 (1.000, 1.001) 0.65
MELD 146 1.036 (0.997, 1.078) 0.072 No
Lactate 100 1.000 (0.997, 1.002) 0.80 No
Vasopressors 150 0.777 (0.363, 1.660) 0.51 No
Renal replacement therapy 150 1.313 (0.598, 2.886) 0.50 No
Mechanical ventilation 150 2.950 (1.199, 7.257) 0.019 Yes 2.880 (1.166, 7.111) 0.022
High coma grade (3 or 4) 148 2.227 (1.017, 4.878) 0.045 No
Late (days 3–5) Unadjusted Multivariable model (N = 113), AUROC = 0.641
N OR 95% OR CI p value Included in model OR 95% CI p value
FABP7 138 1.000 (0.999, 1.001) 0.96 Yes 1.000 (0.999, 1.001) 0.57
MELD 118 1.030 (0.994, 1.066) 0.10 No
Lactate 53 1.031 (0.979, 1.086) 0.25 No
Vasopressors 138 2.043 (0.947, 4.408) 0.069 No
Renal replacement therapy 138 1.756 (0.789, 3.909) 0.17 No
Mechanical ventilation 138 10.115 (2.300, 44.491) 0.0022 No
High coma grade (3 or 4)* 113 24.324 (1.326, 446.243) 0.0316 Yes 25.759 (1.404, 472.46) 0.029
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a hyperdynamic circulation frequently occurring in ALF 
leading to an increased myocardial demand, FABP3 may 
be confounded with myocardial injury. Therefore, FABP7 
is more specific to brain injury in ALF.
FABP7 has physiological properties that render this 
protein advantageous as a prognostic biomarker in 
ALF: (i) it is abundantly present in astrocytes (between 
approximately 0.8 and 3.1 μg/g of brain tissue), (ii) it has 
a lower molecular mass (14 kDa); it is smaller than S-100b 
(21  kDa), enolase (47  kDa) and GFAP (50  kDa) with a 
much shorter plasma half-life (11  min) [31–33]. Smaller 
proteins such as FABP7 diffuse more rapidly (via transcy-
tosis) than larger proteins though the interstitial space and 
cross the blood–brain barrier (BBB).
The release of cerebrovascular proteins into blood 
plasma is dependent on the status (breakdown) of the 
BBB, which in ALF is dependent on the underlying mech-
anisms of cerebral edema, cytotoxic and vasogenic [34]. 
Astrocyte swelling plays a definitive role in the develop-
ment of cytotoxic brain edema. In cytotoxic edema, the 
BBB is intact in the presence of intracellular swelling [35], 
whereas in vasogenic edema there is breakdown of the 
BBB and water and plasma constituents accumulate in 
the extracellular space [36]. Although a complete break-
down of the blood–brain barrier is not evident in ALF, 
increased permeation to water and other small molecules 
such as ammonia has been demonstrated resulting from 
subtle alterations in the protein composition of paracel-
lular tight junctions [37].
Despite elevated levels in ALF patients (survivors and 
non-survivors) in this analysis, FABP7 did not discrimi-
nate between patients who went on to develop significant 
signs of ICH/CE either on imaging, ICP measurements 
or at death. One explanation is that variability in BBB 
permeability during ICH/CE could impact the diffusion 
rate of FABP7 into the peripheral circulation. In this 
study, we speculate that heterogeneity in the permeability 
of the BBB in ALF patients likely impacted the discrimi-
natory ability of serum FABP7 measurements and impor-
tant neurological outcomes in ALF. While FABP7 in 
cerebrospinal fluid may be more discriminatory between 
patients with and without astrocyte swelling/injury, this 
would not be feasible as a noninvasive biomarker as it 
would require an interventricular drain.
Limitations
The following limitations of this study warrant con-
sideration. It is a nested case–control study, and as 
such the event rate of the primary outcome (21-day 
mortality) was 50%, higher than published in cohort 
series. Although patients were enrolled and samples 
were collected prospectively, analysis was performed 
retrospectively and therefore can comment on asso-
ciation and discrimination (between survivors and 
non-survivors) and not on the absolute risks of death 
and intracranial complications according to serum 
FABP7 levels. To account for potential confounding in 
the study design, we performed multivariable analy-
sis to adjust for other significant covariates reflecting 
severity of illness (MELD, vasopressors, mechanical 
ventilation, hepatic coma grade). To avoid confound-
ing related to LT since transplant listing decisions for 
APAP-ALF and the organ availability were not con-
sistent between study centers (Simmons et al., ALFSG 
unpublished data), samples from patients who received 
a LT were not evaluated in this study. The case–con-
trol design of the study may have introduced selection 
bias, as the primary outcome of survival is automati-
cally unbalanced within the clinical profile of the 
groups. However, in an attempt to reduce observa-
tion bias, data were collected prospectively and within 
this specific study design, researchers measuring 
FABP7 were blinded to the clinical and outcome data 
of patients at the time of patient selection and sam-
ple analysis. Finally, we acknowledge that determina-
tions of ICH were done retrospectively using available 
data from death summaries: cranial imaging and ICP 
measurements (if a monitor was used), and this may 
have introduced further bias. The decision to order 
computed tomography of the brain and the use of ICP 
monitors were individual decisions made by the prac-
ticing clinician, and these were not standardized across 
the ALFSG registry and may have varied between 
centers. While renal function may have impacted 
serum FABP7 levels, we attempted to adjust for this 
by including renal function (MELD) in multivariable 
analysis. Nonetheless despite these limitations, we 
believe these results are robust as they include APAP-
ALF cases from across 16 tertiary liver transplant cent-
ers comprising the US ALFSG and are the first report 
of FABP7 in acute liver failure.
Conclusions
Brain FABP levels were elevated in APAP-ALF patients 
with significantly higher serum levels at early and late 
time points in APAP-ALF non-survivors. However, sig-
nificant differences in FABP7 levels by 21-day mortal-
ity were not ascertained after adjusting for significant 
covariates reflecting severity of illness (MELD, vaso-
pressor dependence). No differences in the FABP7 levels 
were detected for APAP-ALF patients with and without 
evidence of ICH/CE. FABP7 does not appear to discrimi-
nate between patients who did and did not have signifi-
cant intracranial complications of APAP-ALF.
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